Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Indapamide + perindopril is a fixed-dose combination medication containing two active ingredients: indapamide (a thiazide-like diuretic) and perindopril (an angiotensin-converting enzyme [ACE] inhibitor). It is primarily used for the treatment of essential hypertension (high blood pressure). Perindopril lowers blood pressure by inhibiting the conversion of angiotensin I to angiotensin II—a potent vasoconstrictor—thereby reducing total peripheral resistance and aldosterone secretion. Indapamide acts mainly by inhibiting sodium and chloride reabsorption in the distal convoluted tubule of the kidney, leading to increased urine output and reduced blood volume; it also has direct effects on vascular smooth muscle. The combination provides synergistic antihypertensive effects with improved arterial compliance and reduced cardiovascular risk compared to monotherapy. Clinical studies have shown that this combination reduces both systolic and diastolic blood pressure effectively in patients with moderate to severe hypertension—including those with diabetes—and may confer additional benefits such as reduction in left ventricular hypertrophy, improved arterial distensibility, renal protection, and decreased risk of microvascular/macrovascular complications[1][2][6][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on indapamide + perindopril.